Výsledky vyhledávání - "I. Sainsbury"

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials

Autor: Josef S Smolen, Ivan Lagunes Galindo, Yihan Li, Roy Fleischmann, Yijie Zhou, I. Sainsbury, Daniel Aletaha

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019)
Arthritis Research & Therapy

Background The ACR20 has been validated as the best discriminator of efficacy in placebo-controlled trials, but not in head-to-head trials comparing effective therapies in patients with rheumatoid arthritis (RA). We assessed the most discriminatory A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eca92e63cd68c26fdddd429ee0dc5cc
https://doi.org/10.1186/s13075-019-2005-9

Zobrazit plný text záznamu

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis

Autor: Stefan Florentinus, Ferdinand C. Breedveld, I. Sainsbury, Hartmut Kupper, Edward C. Keystone, Y. Li

Publikováno v: RMD Open

Objective To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb0bdb8260d49de352a68b5c4bd17b2f
http://europepmc.org/articles/PMC6018859

Zobrazit plný text záznamu

THU0185 The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate

Autor: I. Sainsbury, Josef S Smolen, P. Noertersheuser, X. Huang, B. Kluender, Kun Chen, G.-R. Burmester, J. Kalabic, R. Oerlemans, S. Florentinus, Nael M. Mostafa

Publikováno v: THURSDAY, 14 JUNE 2018.

Background Low trough levels of the tumour necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response at later time points in patients (pts) with rheumatoid arthritis (RA).1 Objecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36b82af33d8fad0a3dfcc69a5c7daa8f
https://doi.org/10.1136/annrheumdis-2018-eular.2721

Zobrazit plný text záznamu

Testing Treat-to-Target Outcomes With Initial Methotrexate Monotherapy Compared With Initial Tumor Necrosis Factor Inhibitor (Adalimumab) Plus Methotrexate in Early Rheumatoid Arthritis

Autor: Ronald F van Vollenhoven, I. Sainsbury, Stefan Florentinus, Benoît Guérette, Josef S Smolen, Paul Emery, Arthur Kavanaugh, Hartmut Kupper, Su Chen, Roy Fleischmann

Publikováno v: Kavanaugh, A, van Vollenhoven, R F, Fleischmann, R, Emery, P, Sainsbury, I, Florentinus, S, Chen, S, Guérette, B, Kupper, H & Smolen, J S 2018, ' Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis ', Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 289-292 . https://doi.org/10.1136/annrheumdis-2017-211871
Annals of the rheumatic diseases, 77(2), 289-292. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 77(2), 289-292. BMJ Publishing Group

ObjectivesTo compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX monotherapy who may have continued receiving MTX or switched t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d7df1ac7889de9099702bdccc5172c
https://eprints.whiterose.ac.uk/123549/9/289.full.pdf

Zobrazit plný text záznamu

THU0110 The importance of sustained remission for longterm outcomes in patients with rheumatoid arthritis

Autor: Josef S Smolen, Y. Zhang, Cem Gabay, Daniel Aletaha, Arthur Kavanaugh, Paul Emery, I. Sainsbury

Publikováno v: Poster Presentations.

Background In patients (pts) with rheumatoid arthritis (RA), the long-term impact of sustained versus (vs) transient clinical remission (REM) has not been assessed thoroughly, although REM duration has been shown to affect structural outcomes 1 . The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43e2be65c30557d66e7f2e1106cba1f9
https://doi.org/10.1136/annrheumdis-2017-eular.2779

Zobrazit plný text záznamu

SAT0047 Predicting maintenance of response based on disease characteristics and early clinical response in rheumatoid arthritis patients upon withdrawal of adalimumab

Autor: Paul Emery, I. Sainsbury, Arthur Kavanaugh, Josef S Smolen, J. Suboticki, H Zhang, X. Wang

Publikováno v: Poster Presentations.

Background Some patients (pts) with rheumatoid arthritis (RA) achieve low disease activity (LDA) after treatment with adalimumab (ADA) plus methotrexate (MTX) and can maintain LDA after ADA withdrawal1. However, others experience a flare in disease a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11e6ef3d13d27861b18ddd4432e2722d
https://doi.org/10.1136/annrheumdis-2017-eular.2503

Zobrazit plný text záznamu

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone

Autor: I. Sainsbury, Désirée van der Heijde, Ronald F van Vollenhoven, Hartmut Kupper, Kun Chen, Ferdinand C. Breedveld, Josef S Smolen, Edward C. Keystone, Paul Emery, Arthur Kavanaugh, Stefan Florentinus

Publikováno v: RMD open, 3(2). BMJ Publishing Group
RMD Open, 3(2):e000445. BMJ Publishing Group
Keystone, E C, Breedveld, F C, Heijde, D V D, Van Vollenhoven, R F, Emery, P, Smolen, J S, Sainsbury, I, Florentinus, S, Kupper, H, Chen, K & Kavanaugh, A 2017, ' Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone ', RMD Open, vol. 3, no. 2, e000445 . https://doi.org/10.1136/rmdopen-2017-000445
RMD Open

Objective To evaluate the achievement of comprehensive disease control (CDC) following 1 year of treatment with adalimumab+methotrexate versus methotrexate alone and whether early achievement of remission (at week 24 or 26) is associated with CDC at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6021f3bde57977a3d8afa9e3da57825
https://pure.amc.nl/en/publications/achieving-comprehensive-disease-control-in-patients-with-early-and-established-rheumatoid-arthritis-treated-with-adalimumab-plus-methotrexate-versus-methotrexate-alone(924de577-3758-40b0-8cb4-787dc46025a9).html

Zobrazit plný text záznamu

AB0315 Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis

Autor: J. Kalabic, F. C. Breedveld, I. Sainsbury, Y. Zhang, E.C. Keystone, Arthur Kavanaugh

Publikováno v: Annals of the Rheumatic Diseases. 75:1008.2-1008

Background In rheumatoid arthritis (RA) patients (pts) receiving corticosteroids (CS) or methotrexate (MTX) with an anti-TNF, such as adalimumab (ADA), the concomitant CS or MTX dose may be reduced if pts respond well or have side-effects. Objectives

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab58362e786aba38b6e9a5b11072e60d
https://doi.org/10.1136/annrheumdis-2016-eular.2389

Zobrazit plný text záznamu

THU0029 Predicting DAS28-CRP <2.6 And Low Disease Activity Status at 6 Months Based on Early Clinical Response in Rheumatoid Arthritis Patients

Autor: Josef S Smolen, I. Sainsbury, X. Wang, A. Kavanaugh

Publikováno v: Annals of the Rheumatic Diseases. 75:187.3-188

Background For patients (pts) with rheumatoid arthritis (RA), early attainment of remission or low disease activity (LDA) predicts better long-term outcomes. Predicting non-response to therapy early in the disease course may avoid additional exposure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21f6a0191d1813c44fcc247a47686527
https://doi.org/10.1136/annrheumdis-2016-eular.1152

Zobrazit plný text záznamu

FRI0118 Does Attainment of Clinical Remission Lead to Comprehensive Disease Control in Rheumatoid Arthritis Patients?: Table 1

Autor: Josef S Smolen, Stefan Florentinus, I. Sainsbury, A. Kavanaugh, Paul Emery, S. Liu, E.C. Keystone

Publikováno v: Annals of the Rheumatic Diseases. 74:463.1-463

Background The primary goal of treating rheumatoid arthritis (RA) is to maximize quality of life through control of signs and symptoms of disease, prevention of structural damage, and normalization of function. Objectives To assess if patients (pts)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec0ae111b3ee0854f3d93f170d041100
https://doi.org/10.1136/annrheumdis-2015-eular.1291

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání